Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | JAVELIN Renal 101: DepOR & outcomes in RCC

Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the depth of response (DepOR) analysis from the JAVELIN Renal 101 trial (NCT02684006), and the correlation with clinical outcomes in renal cell cancer (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.